Clinical trials: Differentiation
Human Immunodeficiency Virus (HIV)
Vitamin D3 Supplementation in Patients With HIV: Effects on Interleukin-6 Levels and CD4 Counts
This study aims to evaluate the effect of Vitamin D3 supplementation on inflammatory markers and immune status in patients with HIV who are receiving antiretroviral therapy.
- Trial name
- NCT07553052
- Testing
- Vitamin D3, Antiretroviral (ARV) medications
- Where
- Indonesia
- Volunteers
- 20 people
- Sponsor
- Universitas Sebelas Maret
Osteoblast, Adipocytes
Effect of Thiazolidinediones on Human Bone
We will prospectively study 2 groups of diabetic patients treated with pioglitazone or placebo for 26 weeks. Bone marrow aspirates will be obtained from these patients at baseline and after 26 weeks of treatment, and hBMCs will…
- Conditions
- Osteoblast, Adipocytes, Bone Density, Osteocalcin
- Trial name
- NCT00927355
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Henoch-Schönlein Purpura Nephritis
Study on Children Henoch-Schönlein Purpura Nephritis With TCM Multistep Treatment
The purpose of this study is to determine the optimum dosage and application method of Glycosides Of Tripterygium Wilfordii Hook(GTW) for Henoch-Schönlein Purpura Nephritis(HSPN) in children, and develop into the normal treatment…
- Trial name
- NCT03591471
- Testing
- Glycosides Of Tripterygium Wilfordii Hook(GTW), Sulfotanshinone Sodium Injection, Chinese herbs based on syndrome differentiation
- Where
- 2 sites in China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Henan University of Traditional Chinese Medicine
Metastatic/Locally Advanced Small-Cell Lung Cancer, Metastatic/Locally Advanced Poorly Differentiated NEC
Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)
UNLOCK TARLATAMAB is an open-label, single arm, multicenter, phase 2 platform study that aims to evaluate the mechanisms of action and resistance to tarlatamab in metastatic/locally advanced Small-Cell Lung Cancer (SCLC) with any…
- Trial name
- NCT07016230
- Testing
- Tarlatamab
- Where
- 3 sites in France
- Volunteers
- 40 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Ectodermal Dysplasia
Ability of a Molecule (Prima) to Restore Physiological Differentiation in Epithelium Expressing Gene p63
Ectodermal dysplasia associated with p63 is a rare disease which, in addition to limbic abnormalities, primarily affects the skin and cornea.
- Trial name
- PRIMAculture (NCT02896387)
- Where
- 2 sites in France
- Volunteers
- 5 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
This phase I trial tests the safety, side effects and best dose of BAY 1895344 when given together with usual chemotherapy (irinotecan or topotecan) in treating patients with solid tumors that may have spread from where it first…
- Conditions
- Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT04514497
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 23 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma
This phase II trial studies how well giving ofatumumab together with bortezomib works in treating patients with relapsed diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), or mantle cell lymphoma (MCL).
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma
- Trial name
- NCT01397591
- Testing
- Ofatumumab, Bortezomib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- OHSU Knight Cancer Institute
Muscle Weakness
Growth Differentiation Factor 15 in ICU Acquired Muscle Weakness
Intensive care unit -acquired weakness (ICU- AW) is a common consequence linked to a worse outcome as evidenced by prolonged mechanical ventilation, longer ICU stays, greater mortality rates and a lower quality of life for…
- Trial name
- NCT06713746
- Testing
- growth differentiation factor 15
- Where
- Egypt
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Minia University
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
This phase I trial is studying the side effects and best dose of 7-hydroxystaurosporine when given together with perifosine in treating patients with relapsed or refractory acute leukemia, chronic myelogenous leukemia, or…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00301938
- Testing
- 7-hydroxystaurosporine, perifosine, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma
Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer
This phase II trial studies how well lenvatinib works when given together with standard of care iodine I-131 in treating patients with radioactive iodine-sensitive differentiated thyroid cancer.
- Conditions
- Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
- Trial name
- NCT03506048
- Testing
- Lenvatinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Emory University
Hiv
Engaging Men Through HIV Self-Testing With Differentiated Care to Improve ART Initiation and Viral Suppression Among Men in Malawi
Men in sub-Saharan Africa who test HIV-positive continue to have poor ART initiation and retention outcomes. The proposed project will test a home-based ART intervention for men who are living with HIV compared to facility-based…
- Trial name
- NCT04858243
- Testing
- Home-Based ART, Facility-Based ART
- Where
- Malawi
- Volunteers
- 930 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Obesity
Clinical and Metabolic, Immunological and Microbiological Characteristics of Obese Patients
The purpose of the study: To develop a differentiated management strategy for obese children based on the analysis of the relationship between their clinical, metabolic, immunological and microbiological status Research…
- Trial name
- NCT05920785
- Testing
- Determination of the level of interleukins in the blood, stool analysis for the intestinal microbiome, general clinical tests, glucose tolerance test, hormonal profile
- Where
- Russia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Samara State Medical University
Differentiated Thyroid Carcinoma
Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma
This is a non-randomized, phase II, open label study of Apatinib Mesylate in patients with with locally advanced or metastatic differentiated thyroid carcinoma (DTC).
- Trial name
- NCT03167385
- Testing
- Apatinib Mesylate
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pancreatic Tumor
Differentiation Benign and Malignant Pancreatic Lesions
The MVIT-MLKA model, with its complex architecture combining CNNs and Transformers, excels in image feature extraction and capturing long-range dependencies.
- Trial name
- D (NCT06641947)
- Testing
- Whipple procedure
- Where
- China
- Volunteers
- 864 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Urothelial Carcinoma, Renal Cell Carcinoma
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT03170960
- Testing
- cabozantinib, atezolizumab
- Where
- 124 sites in United States, Australia and 7 more
- Volunteers
- 914 people
- Sponsor
- Exelixis
Cervical Cancer
Efficacy of Chemotherapy Alone in Patients With Poor-differentiated Early-stage Cervical Cancer
This study is aimed to enroll patients with early-stage cervical cancer (FIGO 2018 IB1-IB2) who undergo radical hysterectomy and the postoperative pathology doesn't meet Sedlis criteria or the "four-factor" model but with poorly…
- Trial name
- NCT05863377
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Drug Safety
Reducing Medication Errors on Basis of an Individual Risk Assessment
Background: Medication reviews performed on admission to hospitals reduce medication errors; however, evidence of effect on morbidity and mortality is currently inconsistent.
- Trial name
- MERIS1 (NCT01814280)
- Testing
- Medication review
- Where
- Denmark
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Radioactive Iodine-refractory Differentiated Thyroid Cancer
Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer
This is a single arm, open-label, non-randomized and single-center phase II clinical study, to evaluate the safety, tolerance, and efficacy of Camrelizumab in combination with Apatinib in patients with Radioactive…
- Trial name
- NCT04560127
- Testing
- Camrelizumab combination with Apatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Thyroid Cancer
Anlotinib and Benmelstobart in DTC
This study is a multicenter, open-label, phase II study to evaluate the efficacy and safety of Benmelstobart in combination with Anlotinib as a second-line treatment for locally advanced or metastatic differentiated thyroid…
- Trial name
- NCT07193186
- Testing
- Anlotinib and Benmelstobart
- Volunteers
- 23 people
- Sponsor
- Fudan University
Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors
This clinical trial evaluates the impact of a patient-centered health and wellness coaching (HWC) intervention on adherence to treatment plans and healthy lifestyle practices in patients with papillary or follicular thyroid…
- Trial name
- NCT07545837
- Testing
- Counseling, Interview, Questionnaire Administration
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic